These findings suggest that SIGIRR protects PPARα-regulated lipid metabolism and mitigates inflammatory responses triggered by external factors during NASH development, highlighting the potential use of SIGIRR agonists as therapeutic strategies (Ref. Here, SIGIRR is linked to metabolic dysfunction-associated steatohepatitis.